Skip to main content
Clinical Trials/ITMCTR2200005822
ITMCTR2200005822Recruiting未知

Treatment of midnight-noon ebb-flow acupuncture for chemotherapy-induced peripheral neuropathy in patients with multiple myeloma

Zhabei Central Hospital in Shanghai Jing'an District0 sitesStarted: TBDLast updated:
Conditions

Trial Snapshot

Phase
未知
Status
Recruiting
Sponsor

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional study

Eligibility Criteria

Sex
All

Inclusion Criteria

  • 1. Patients diagnosed with MM; 2. Patients without PN at baseline, those experiencing PN grade 2 or above after Bortezomib chemotherapy (the severity of neuropathy was evaluated according to NCI CTCAE, version 3.0); Electromyography examination suggesting conduction disorders of the median and peroneal nerves, slowing down of one item or more items of NCV; 3. Willing to terminate chemotherapy for three months and receive treatment using this method; Patients who signed informed consent.

Exclusion Criteria

  • 1. Patients who were pregnant; 2. Those with severe heart, liver, and kidney dysfunction or other critical diseases (such as malignant tumors); 3. Those with PN caused by reasons other than chemotherapy, such as plasma cell tumor compression, nutritional disorders, and infection; 4. Those with platelet count < 30 × 109/L and white blood cell count < 3.0 × 109/L before the treatment; 5. Patients who were unable to communicate due to severe cognitive disorder; 6. Those who did not cooperate or refused to sign informed consent.

Investigators

Sponsor
Zhabei Central Hospital in Shanghai Jing'an District

Similar Trials